argenx NV ADR (ARGX)vsGenmab AS (GMAB)
ARGX
argenx NV ADR
$697.05
+2.89%
HEALTHCARE · Cap: $42.05B
GMAB
Genmab AS
$26.11
+1.16%
HEALTHCARE · Cap: $15.94B
Smart Verdict
WallStSmart Research — data-driven comparison
argenx NV ADR generates 14% more annual revenue ($4.24B vs $3.72B). ARGX leads profitability with a 30.5% profit margin vs 25.9%. ARGX appears more attractively valued with a PEG of 0.83. ARGX earns a higher WallStSmart Score of 63/100 (C+).
ARGX
Buy63
out of 100
Grade: C+
GMAB
Buy54
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-526.8%
Fair Value
$133.14
Current Price
$697.05
$563.91 premium
Margin of Safety
-187.1%
Fair Value
$10.47
Current Price
$26.11
$15.64 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Keeps 31 of every $100 in revenue as profit
Revenue surging 73.0% year-over-year
Every $100 of equity generates 20 in profit
Growing faster than its price suggests
Strong operational efficiency at 27.4%
Reasonable price relative to book value
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Keeps 26 of every $100 in revenue as profit
Attractively priced relative to earnings
Strong operational efficiency at 23.0%
Areas to Watch
Premium valuation, high expectations priced in
Weak financial health signals
Earnings declined 31.9%
Expensive relative to growth rate
3.0% revenue growth
Weak financial health signals
Earnings declined 94.4%
Comparative Analysis Report
WallStSmart ResearchBull Case : ARGX
The strongest argument for ARGX centers on Profit Margin, Revenue Growth, Return on Equity. Profitability is solid with margins at 30.5% and operating margin at 27.4%. Revenue growth of 73.0% demonstrates continued momentum.
Bull Case : GMAB
The strongest argument for GMAB centers on Price/Book, Debt/Equity, Altman Z-Score. Profitability is solid with margins at 25.9% and operating margin at 23.0%.
Bear Case : ARGX
The primary concerns for ARGX are P/E Ratio, Piotroski F-Score, EPS Growth.
Bear Case : GMAB
The primary concerns for GMAB are PEG Ratio, Revenue Growth, Piotroski F-Score.
Key Dynamics to Monitor
ARGX profiles as a growth stock while GMAB is a value play — different risk/reward profiles.
GMAB carries more volatility with a beta of 0.75 — expect wider price swings.
ARGX is growing revenue faster at 73.0% — sustainability is the question.
GMAB generates stronger free cash flow (1.8B), providing more financial flexibility.
Bottom Line
ARGX scores higher overall (63/100 vs 54/100), backed by strong 30.5% margins and 73.0% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
argenx NV ADR
HEALTHCARE · BIOTECHNOLOGY · USA
argenx SE, a clinical-phase biotechnology company, focuses on the development of antibody-based therapies for the treatment of autoimmune diseases, hematology and cancer. The company is headquartered in Breda, the Netherlands.
Genmab AS
HEALTHCARE · BIOTECHNOLOGY · USA
Genmab A / S develops antibody therapies for the treatment of cancer and other diseases mainly in Denmark. The company is headquartered in Copenhagen, Denmark.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?